Spectral Medical company

Sepsis affects approximately 1,000,000 patients in the U.S. alone each year and millions worldwide. The ability to rapidly and accurately diagnose and treat this deadly disease remains one of the biggest challenges faced by healthcare professionals today. Using a unique and innovative theranostics approach, Spectral Diagnostics is committed to decreasing the unacceptably high mortality rates caused by sepsis. By combining complementary diagnostics and therapeutics, or theranostics, Spectral’s vision is to provide products that will enable vastly improved outcomes of patients with severe sepsis.
Technology: P4 Medicine
Industry: Biotechnology, Health Care, Science and Engineering
Headquarters: Toronto, Ontario, Canada
Founded Date: 1991-01-01
Employees Number: 11-50
Funding Status: IPO
Investors Number: 7
Total Funding: $1.1M
Estimated Revenue: $1M to $10M
Last Funding Type: Seed

Visit Website
info@spectraldx.com
https://twitter.com/invisionai
Register and Claim Ownership